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Loss of heterozygosity of the oestrogen receptor gene in breast cancer
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Suary DNA from 67 primary breast carcinoma biopsies has been examined for loss of heterozygosity
(LOH) using the microsatellite (TA), repeat marker positioned 1 kb upstream of the oestrogen receptor (ER)
gene. Forty-seven (70.1%) of the cases were informative; nine of these (19.1%) were positive for LOH. In
three of the nine cases, there was total loss, and in the other six cases there was a marked reduction in th-
intensity of signal from one allele. LOH correlated weakly with histological grade and age, but not with ER
status. This result suggests that LOH of the ER gene does not have an imnportant role in the lack of ER
function in breast cancer tissues.
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Human breast cancer is one of the typical hormone-depen-
dent tumours, and approximately one-third of breast cancer
patients respond to endocrine therapy (Rubens et al., 1980).
The oestrogen receptor (ER) is a 66 kDa intranuclear protein
consisting of six functional domains and is a ligand-activated
transcription factor (Ponglilitmongkol et al., 1988). Cur-
rently, ER content in tumours is not used to predict those
patients who might benefit from endocrine therapy. ER
status also provides prognostic information (Stewart et al.,
1982). Tumours lacking ER and progesterone receptor (PgR)
generally grow faster than tumours containing both ER and
PgR (McGuire and Clark, 1989).
Genetic alterations are believed to play an important role
in the origin and dissemination of breast cancer (Sato et al.,
1991). Frequent loss of heterozygosity (LOH) in breast
tumour DNA, which implies the presence of a tumour-sup-
pressor gene, has been detected on chromosomes lq, 3p, 6q,
7q, lIp, 13q, 16q, 17p, 17q and 18q (Devilee et al., 1991;
Pathak et al., 1991; Sato et al., 1991; Thorlacius et al., 1991;
Andersen et al., 1992; Bieche et al., 1992; Knyazev et al.,
1993). The ER gene is located on chromosome 6q25.1 (Men-
asce et al., 1993), and its total size, including introns, is
about 140kb (Ponglikitmongkol et al., 1988). LOH at the
ER locus on chromosome 6q has previously been reported in
human ovarian carcinomas (Lee et al., 1990) and in human
breast cancer (Devilee et al., 1991).
In this report, we examined LOH on the ER gene in 67
breast cancer patients using a highly informative microsatel-
lite TA repeat marker positioned 1 kb upstream of the ER
gene (Senno et al., 1992). We also analysed the relationship
between LOH of the ER gene and ER content, as well as
other clinicopathological parameters.
Patients and methods
Patients and DNA preparations
Tissue from 67 breast carcinomas was obtained from the
tissue bank of the breast unit at Guy's Hospital, London. Of
the 67 tumours, 58 were infiltrating ductal carcinoma and
nine were special types, including six infiltrating lobular car-
cinomas. The histopathological classifications were carried
out according to the World Health Organization typing
scheme for breast tumours (WHO, 1981). Patients were
graded histopathologically according to the modified Bloom
and Richardson method of Elston and Ellis, (1991). Blood
samples also were taken from each patient. Genomic DNA
from the breast cancer specimens and the blood samples was
extracted by standard techniques (Sambrook et al., 1989).
Oestrogen andprogesterone receptor determinations
Cytosolic ER and PgR levels were measured using enzyme
immunoassay (ER- and PgR-EIA, Abbott Laboratories,
Chicago, IL, USA). Positive ER and PgR status was defined
as more than 20 fmol mg'- protein.
Microsatellite (TA), repeat polymorphism
The polymorphic (TA),, repeat (Weissenbach, 1993) was
identified in the upstream region of the human ER gene
(Senno et al., 1992). Polymerase chain reaction (PCR) assays
(Saiki et al., 1985) were performed using 32P-labelled primers
in 25IlI of a buffer containing 1.5 mM magnesium chloride,
0.5mM DNTPS and 50-lOOng of human tumour or blood
DNA. PCR primers were: ER-1, 5'-GACGCATGATATACT-
TCACC-3' (TA strand); and ER-2, 5'-GCAGAATCAAAT-
ATCCAGATG-3' (AT strand). Amplification conditions
were as follows: denaturation for 5 min at 94°C: followed by
19 cycles at 94°C for 1 min, 58°C for 1 min, 72'C for 1.5 min
and a final extension at 72°C for 5 min. The PCR products
were separated by electrophoresis on a 5% denaturing poly-
acrylamide gel, and alleles were detected by autoradio-
graphy.
Statistical analvsis
All comparisons between LOH and clinicopathological
parameters were performed using the Kendall test. P-values
<0.05 were considered statistically significant.
Results
Loss ofheterozygositv ofthe ER gene
The DNAs from a total of 67 tumours were studied for allele
loss using the dinucleotide TA repeat microsatellite marker,
positioned just upstream of the ER gene. Constitutional
heterozygosity was observed in 47 cases (70.1%), and, of
these, clear LOH was seen in nine (19.1%) (Figure 1). In
three cases (DNA nos. 185, 120 and 256) there was complete
loss, but in the other six cases (nos. 34, 39, 67, 207, 813 and
894) there was a marked reduction in the intensity of signal
from one allele. This residual signal could be due to the
presence of normal cells within the tumour sample. Normal
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Figwe 1 Examples of loss of heterozygosity (LOH): sample 1
shows constitutional homozygosity, sample 2 shows normal dip-
loid genotype and samples 3, 4 and 5 show LOH (sample 3; a
marked reduction in the intensity of signal from one allele). T
and L indicate, respectively, tumour and lymphocyte genomic
DNA from the same patient.
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with high histological grade and age at surgery. There was no
relationship between LOH and other clinicopathological
parameters, such as tumour size, metastatic nodal status or
hormone receptor status. Figure 2 shows a quantitative
assessment of ER value vs LOH of the ER gene and demon-
strates that there was no relationship between them.
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In the early stages of human breast cancer the proliferation
of tumour cells depends on oestrogen. After that, the cancer
cells may acquire new proliferative pathways sequentially as
a result of multiple genetic alterations. This then enables the
tumour cells to bypass the oestrogen-dependent proliferation
(Liu et at., 1988). Although there are many reports concern-
ing variant ER genes (Sluyser, 1992; Fuqua et al., 1993;
Pfeffer et at., 1993), the reason for the existence of ER-
negative breast cancer is still not understood.
Table I Relationship with cinicopathological parameters
LOH No LOH Total P
ER status
Positive 4 (16.0%) 21 (84.0%) 25 NS
Negative 5 (22.7%) 17 (77.3%) 22
PgR status
Positive 5 (19.2%) 21 (80.8%) 26 NS
Negative 4 (19.0%) 17 (81.0%) 21
Age at surgery (years)
<50 1 (7.1%) 13 (92.9%) 14 P=0048
,50 8 (24.2%) 25 (75.8%) 33
Tumour size
<,2.0 (cm) 4 (23.5%) 13 (76.5%) 17 NS
>2.0 4 (14.3%) 24 (85.7%) 28
Metastatic nodal status
Positive 4 (25.0%) 12 (75.0%) 16 NS
Negative 5 (18.8%) 23 (81.2%) 28
Histological grade
I 0 1 1
II 1 (6.3%) 15 (93.7%) 16 P = 0.015
III 6 (27.3%) 16 (72.7%) 22
'Histological grade was obtained in the patients with infiltrating
ductal carcinoma.
We initially hypothesised that breast cancer with negative
ER might be induced by the mutation of one allele and loss
or replacement of a chromosomal segment containing the
other allele. We used a highly informative polymorphic
marker located very close to the ER gene to test this
hypothesis. Our results suggest that, although LOH on the
ER gene was seen in about 19% of the informative cases,
there was no relationship between LOH and ER status. This
indicated that allele loss may not play an important role in
the lack of ER function in breast cancer tissues. Devilee et al.
(1991) reported that the frequency of LOH on 6q was as high
as 50%, and also found no relationship between LOH on 6q
and ER status using the markers D6S37 and MYB (locus
6q27 and 6q22-q23 respectively).
On the other hand, it is possible for LOH to be randomly
acquired and irrelevant to tumour development (Chen et al.,
1992). The background incidence of random allelic losses
may be higher in later stage lesions because they have had a
longer time for randomly acquired lesions to be co-selected
with other mutations which confer a selective advantage
associated with malignant progression. The frequency of
background LOH has been reported as 4-15% (Sato et al.,
1990; Chen et al., 1992). In our case, the incidence of LOH
on the ER gene might be higher than the background
LOH.
In summary, we found no relationship between LOH on
the ER gene and the lack of ER function in breast cancer
tissue. Further molecular investigation is therefore required
to understand the molecular basis of ER-negative breast
cancer.
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